Mizuho lowered shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a buy rating to a neutral rating in a research note released on Wednesday morning. Mizuho currently has $16.00 price target on the biotechnology company’s stock.
IRWD has been the topic of several other research reports. BidaskClub upgraded Ironwood Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, August 25th. ValuEngine upgraded Ironwood Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, September 1st. Morgan Stanley restated a hold rating on shares of Ironwood Pharmaceuticals in a research report on Monday. Credit Suisse Group initiated coverage on Ironwood Pharmaceuticals in a research report on Monday, November 27th. They set a buy rating and a $19.00 price objective on the stock. Finally, Cowen set a $20.00 price objective on Ironwood Pharmaceuticals and gave the stock a buy rating in a research report on Monday, August 21st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $17.88.
Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) traded down $0.68 on Wednesday, hitting $15.12. The stock had a trading volume of 1,900,300 shares, compared to its average volume of 1,308,709. Ironwood Pharmaceuticals has a one year low of $13.43 and a one year high of $19.94. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The company had revenue of $86.80 million for the quarter, compared to analyst estimates of $73.59 million. During the same quarter last year, the company posted ($0.18) EPS. The company’s revenue for the quarter was up 31.3% compared to the same quarter last year. equities research analysts expect that Ironwood Pharmaceuticals will post -1.12 earnings per share for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in Ironwood Pharmaceuticals by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 10,761,867 shares of the biotechnology company’s stock worth $203,184,000 after purchasing an additional 256,406 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $150,460,000. State Street Corp grew its holdings in shares of Ironwood Pharmaceuticals by 13.7% in the second quarter. State Street Corp now owns 4,530,267 shares of the biotechnology company’s stock valued at $85,533,000 after acquiring an additional 545,464 shares in the last quarter. EcoR1 Capital LLC grew its holdings in shares of Ironwood Pharmaceuticals by 29.2% in the second quarter. EcoR1 Capital LLC now owns 3,753,635 shares of the biotechnology company’s stock valued at $70,869,000 after acquiring an additional 848,120 shares in the last quarter. Finally, Pictet Asset Management Ltd. grew its holdings in shares of Ironwood Pharmaceuticals by 37.5% in the third quarter. Pictet Asset Management Ltd. now owns 2,622,507 shares of the biotechnology company’s stock valued at $41,357,000 after acquiring an additional 715,147 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thestockobserver.com/2017/12/07/ironwood-pharmaceuticals-irwd-downgraded-to-neutral-at-mizuho.html.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.